Abstract
The molecular processes governing hematopoiesis involve the interplay between lineage-specific transcription factors and a series of epigenetic tags, including DNA methylation and covalent histone tail modifications, such as acetylation, methylation, phosphorylation, SUMOylation and ubiquitylation. These post-translational modifications, which collectively constitute the ‘histone code’, are capable of affecting chromatin structure and gene transcription and are catalysed by opposing families of enzymes, allowing the developmental potential of hematopoietic stem cells to be dynamically regulated. The essential role of these enzymes in regulating normal blood development is highlighted by the finding that members from all families of chromatin regulators are targets for dysregulation in many hematological malignancies, and that patterns of histone modification are globally affected in cancer as well as the regulatory regions of specific oncogenes and tumor suppressors. The discovery that these epigenetic marks can be reversed by compounds targeting aberrant transcription factor/co-activator/co-repressor interactions and histone-modifying activities, provides the basis for an exciting field in which the epigenome of cancer cells may be manipulated with potential therapeutic benefits.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aagaard L, Laible G, Selenko P, Schmid M, Dorn R, Schotta G et al. (1999). Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31. EMBO J 18: 1923–1938.
Aasland R, Gibson TJ, Stewart AF . (1995). The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biochem Sci 20: 56–59.
Ahluwalia A, Hurteau JA, Bigsby RM, Nephew KP . (2001). DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 82: 299–304.
Ahmad K, Henikoff S . (2002). The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell 9: 1191–1200.
Ait-Si-Ali S, Guasconi V, Fritsch L, Yahi H, Sekhri R, Naguibneva I et al. (2004). A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. EMBO J 23: 605–615.
Allis CD, Bowen JK, Abraham GN, Glover CV, Gorovsky MA . (1980). Proteolytic processing of histone H3 in chromatin: a physiologically regulated event in tetrahymena micronuclei. Cell 20: 55–64.
Ambros V, Chen X . (2007). The regulation of genes and genomes by small RNAs. Development 134: 1635–1641.
Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P . (2001). NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 74: 79–88.
Antequera F, Bird A . (1993). Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 90: 11995–11999.
Aravin A, Gaidatzis D, Pfeffer S, Lagos-Quintana M, Landgraf P, Iovino N et al. (2006). A novel class of small RNAs bind to MILI protein in mouse testes. Nature 442: 203–207.
Ayton PM, Cleary ML . (2003). Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev 17: 2298–2307.
Balint BL, Gabor P, Nagy L . (2005a). Genome-wide localization of histone 4 arginine 3 methylation in a differentiation primed myeloid leukemia cell line. Immunobiology 210: 141–152.
Balint BL, Szanto A, Madi A, Bauer UM, Gabor P, Benko S et al. (2005b). Arginine methylation provides epigenetic transcription memory for retinoid-induced differentiation in myeloid cells. Mol Cell Biol 25: 5648–5663.
Bao N, Lye KW, Barton MK . (2004). MicroRNA binding sites in Arabidopsis class III HD-ZIP mRNAs are required for methylation of the template chromosome. Dev Cell 7: 653–662.
Begley CG, Aplan PD, Davey MP, Nakahara K, Tchorz K, Kurtzberg J et al. (1989). Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci USA 86: 2031–2035.
Belinsky SA, Klinge DM, Stidley CA, Issa JP, Herman JG, March TH et al. (2003). Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 63: 7089–7093.
Bell AC, Felsenfeld G . (2000). Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405: 482–485.
Bernstein BE, Meissner A, Lander ES . (2007). The mammalian epigenome. Cell 128: 669–681.
Bird A . (2002). DNA methylation patterns and epigenetic memory. Genes Dev 16: 6–21.
Blobel GA . (2002). CBP and p300: versatile coregulators with important roles in hematopoietic gene expression. J Leukoc Biol 71: 545–556.
Blobel GA, Sieff CA, Orkin SH . (1995). Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol Cell Biol 15: 3147–3153.
Bottardi S, Ghiam AF, Bergeron F, Milot E . (2007). Lineage-specific transcription factors in multipotent hematopoietic progenitors: a little bit goes a long way. Cell Cycle 6: 1035–1039.
Boyes J, Byfield P, Nakatani Y, Ogryzko V . (1998). Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594–598.
Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660–665.
Breuer RH, Snijders PJ, Smit EF, Sutedja TG, Sewalt RG, Otte AP et al. (2004). Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 6: 736–743.
Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT . (2006). Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 10: 51–68.
Butcher DT, Rodenhiser DI . (2007). Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur J Cancer 43: 210–219.
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103–107.
Canote R, Du Y, Carling T, Tian F, Peng Z, Huang S . (2002). The tumor suppressor gene RIZ in cancer gene therapy (review). Oncol Rep 9: 57–60.
Cao R, Tsukada Y, Zhang Y . (2005). Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 20: 845–854.
Carbone R, Botrugno OA, Ronzoni S, Insinga A, Di Croce L, Pelicci PG et al. (2006). Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26: 1288–1296.
Carrozza MJ, Li B, Florens L, Suganuma T, Swanson SK, Lee KK et al. (2005). Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell 123: 581–592.
Cebrian A, Pharoah PD, Ahmed S, Ropero S, Fraga MF, Smith PL et al. (2006). Genetic variants in epigenetic genes and breast cancer risk. Carcinogenesis 27: 1661–1669.
Chen T, Tsujimoto N, Li E . (2004). The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA methylation to the major satellite repeats at pericentric heterochromatin. Mol Cell Biol 24: 9048–9058.
Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . (1998). The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92: 3025–3034.
Chevillard-Briet M, Trouche D, Vandel L . (2002). Control of CBP co-activating activity by arginine methylation. EMBO J 21: 5457–5466.
Cowger JJ, Zhao Q, Isovic M, Torchia J . (2007). Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence. Oncogene 26: 3378–3386.
Cress WD, Seto E . (2000). Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1–16.
Daser A, Rabbitts TH . (2005). The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol 15: 175–188.
de la Serna IL, Ohkawa Y, Imbalzano AN . (2006). Chromatin remodelling in mammalian differentiation: lessons from ATP-dependent remodellers. Nat Rev Genet 7: 461–473.
Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M et al. (2002). Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295: 1079–1082.
Dou Y, Milne TA, Tackett AJ, Smith ER, Fukuda A, Wysocka J et al. (2005). Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121: 873–885.
Douglas J, Coleman K, Tatton-Brown K, Hughes HE, Temple IK, Cole TR et al. (2005). Evaluation of NSD2 and NSD3 in overgrowth syndromes. Eur J Hum Genet 13: 150–153.
Dover GJ, Brusilow S, Samid D . (1992). Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 327: 569–570.
Duprez E, Wagner K, Koch H, Tenen DG . (2003). C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J 22: 5806–5816.
Ernst P, Mabon M, Davidson AJ, Zon LI, Korsmeyer SJ . (2004). An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr Biol 14: 2063–2069.
Ernst P, Wang J, Huang M, Goodman RH, Korsmeyer SJ . (2001). MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein. Mol Cell Biol 21: 2249–2258.
Ernst P, Wang J, Korsmeyer SJ . (2002). The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol 9: 282–287.
Esteller M . (2003). Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109: 80–88.
Fan HY, He X, Kingston RE, Narlikar GJ . (2003). Distinct strategies to make nucleosomal DNA accessible. Mol Cell 11: 1311–1322.
Fatemi M, Wade PA . (2006). MBD family proteins: reading the epigenetic code. J Cell Sci 119: 3033–3037.
Fazi F, Travaglini L, Carotti D, Palitti F, Diverio D, Alcalay M et al. (2005). Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. Oncogene 24: 1820–1830.
Forneris F, Binda C, Dall'Aglio A, Fraaije MW, Battaglioli E, Mattevi A . (2006). A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem 281: 35289–35295.
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391–400.
Fraga MF, Esteller M . (2005). Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 4: 1377–1381.
Galm O, Herman JG, Baylin SB . (2006). The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 20: 1–13.
Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS et al. (2007). Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 128: 505–518.
Ge YZ, Pu MT, Gowher H, Wu HP, Ding JP, Jeltsch A et al. (2004). Chromatin targeting of de novo DNA methyltransferases by the PWWP domain. J Biol Chem 279: 25447–25454.
Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T et al. (2005). 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25: 4727–4741.
Glinsky GV, Berezovska O, Glinskii AB . (2005). Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115: 1503–1521.
Goddard AD, Borrow J, Freemont PS, Solomon E . (1991). Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371–1374.
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. (2006). Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361–6369.
Goto T, Monk M . (1998). Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev 62: 362–378.
Gray SG, Iglesias AH, Lizcano F, Villanueva R, Camelo S, Jingu H et al. (2005). Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem 280: 28507–28518.
Grewal SI, Elgin SC . (2007). Transcription and RNA interference in the formation of heterochromatin. Nature 447: 399–406.
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M et al. (1998). Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391: 815–818.
Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V et al. (2006). Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 8: 764–770.
Guidez F, Howell L, Isalan M, Cebrat M, Alani RM, Ivins S et al. (2005). Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol 25: 5552–5566.
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A et al. (1998). Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18: 126–135.
Huang S, Brandt SJ . (2000). mSin3A regulates murine erythroleukemia cell differentiation through association with the TAL1 (or SCL) transcription factor. Mol Cell Biol 20: 2248–2259.
Huang S, Qiu Y, Shi Y, Xu Z, Brandt SJ . (2000). P/CAF-mediated acetylation regulates the function of the basic helix–loop–helix transcription factor TAL1/SCL. EMBO J 19: 6792–6803.
Huang S, Qiu Y, Stein RW, Brandt SJ . (1999). p300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein. Oncogene 18: 4958–4967.
Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM et al. (2007). Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 104: 8023–8028.
Hung HL, Lau J, Kim AY, Weiss MJ, Blobel GA . (1999). CREB-binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Mol Cell Biol 19: 3496–3505.
Huo X, Zhang J . (2005). Important roles of reversible acetylation in the function of hematopoietic transcription factors. J Cell Mol Med 9: 103–112.
Ikegami K, Iwatani M, Suzuki M, Tachibana M, Shinkai Y, Tanaka S et al. (2007). Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Genes Cells 12: 1–11.
Ivascu C, Wasserkort R, Lesche R, Dong J, Stein H, Thiel A et al. (2007). DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas. Int J Biochem Cell Biol 39: 1523–1538.
Jaju RJ, Fidler C, Haas OA, Strickson AJ, Watkins F, Clark K et al. (2001). A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 98: 1264–1267.
Jenuwein T, Allis CD . (2001). Translating the histone code. Science 293: 1074–1080.
Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R et al. (2006). Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66: 11341–11347.
Kamashev D, Vitoux D, De Thé H . (2004). PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199: 1163–1174.
Kapoor A, Agius F, Zhu JK . (2005). Preventing transcriptional gene silencing by active DNA demethylation. FEBS Lett 579: 5889–5898.
Kasper LH, Boussouar F, Ney PA, Jackson CW, Rehg J, van Deursen JM et al. (2002). A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature 419: 738–743.
Kastner P, Lawrence HJ, Waltzinger C, Ghyselinck NB, Chambon P, Chan S . (2001). Positive and negative regulation of granulopoiesis by endogenous RARalpha. Blood 97: 1314–1320.
Kawasaki H, Schiltz L, Chiu R, Itakura K, Taira K, Nakatani Y et al. (2000). ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature 405: 195–200.
Kim DY, Choi SJ, Kim SH, Chung HY, Yi S, Kim DW et al. (2005). Upregulated hoxC4 induces CD14 expression during the differentiation of acute promyelocytic leukemia cells. Leuk Lymphoma 46: 1061–1066.
Kim KC, Geng L, Huang S . (2003). Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 63: 7619–7623.
Kishigami S, Van Thuan N, Hikichi T, Ohta H, Wakayama S, Mizutani E et al. (2006). Epigenetic abnormalities of the mouse paternal zygotic genome associated with microinsemination of round spermatids. Dev Biol 289: 195–205.
Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G . (1998). Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J 17: 3714–3725.
Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML et al. (2007). Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 25: 473–481.
Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T et al. (2002). Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet 30: 365–366.
Langst G, Becker PB . (2001). ISWI induces nucleosome sliding on nicked DNA. Mol Cell 8: 1085–1092.
Lee KK, Workman JL . (2007). Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol 8: 284–295.
Lee MG, Norman J, Shilatifard A, Shiekhattar R . (2007). Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb-like protein. Cell 128: 877–887.
Lee MG, Wynder C, Bochar DA, Hakimi MA, Cooch N, Shiekhattar R . (2006). Functional interplay between histone demethylase and deacetylase enzymes. Mol Cell Biol 26: 6395–6402.
Lessard J, Sauvageau G . (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255–260.
Letting DL, Rakowski C, Weiss MJ, Blobel GA . (2003). Formation of a tissue-specific histone acetylation pattern by the hematopoietic transcription factor GATA-1. Mol Cell Biol 23: 1334–1340.
Levings PP, Bungert J . (2002). The human beta-globin locus control region. Eur J Biochem 269: 1589–1599.
Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, Wang YC . (2007). Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 55: 205–213.
Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL et al. (2005). Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65: 1277–1284.
Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ . (1997). Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 389: 251–260.
Mahadevan D, Spier C, Della Croce K, Miller S, George B, Riley C et al. (2005). Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 4: 1867–1879.
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. (1995). The nuclear receptor superfamily: the second decade. Cell 83: 835–839.
Melnick A, Carlile G, Ahmad KF, Kiang CL, Corcoran C, Bardwell V et al. (2002). Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Mol Cell Biol 22: 1804–1818.
Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH et al. (2005). LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437: 436–439.
Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al. (2002). MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 10: 1107–1117.
Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S et al. (2000). Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5: 811–820.
Minucci S, Pelicci PG . (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38–51.
Mukherjee S, Berger MF, Jona G, Wang XS, Muzzey D, Snyder M et al. (2004). Rapid analysis of the DNA-binding specificities of transcription factors with DNA microarrays. Nat Genet 36: 1331–1339.
Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R et al. (2002). ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 10: 1119–1128.
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN et al. (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386–389.
O'Geen H, Squazzo SL, Iyengar S, Blahnik K, Rinn JL, Chang HY et al. (2007). Genome-wide analysis of KAP1 binding suggests autoregulation of KRAB-ZNFs. PLoS Genet 3: e89.
O'Neil J, Shank J, Cusson N, Murre C, Kelliher M . (2004). TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5: 587–596.
Oberley MJ, Tsao J, Yau P, Farnham PJ . (2004). High-throughput screening of chromatin immunoprecipitates using CpG-island microarrays. Methods Enzymol 376: 315–334.
Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM et al. (2005). hDOT1L links histone methylation to leukemogenesis. Cell 121: 167–178.
Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y . (2006). Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 8: 1017–1024.
Okano M, Xie S, Li E . (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19: 219–220.
Ostler KR, Davis EM, Payne SL, Gosalia BB, Exposito-Cespedes J, Beau MM et al. (2007). Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene (in press).
Ouaissi M, Ouaissi A . (2006). Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. J Biomed Biotechnol 2006: 13474.
Pahlich S, Zakaryan RP, Gehring H . (2006). Protein arginine methylation: cellular functions and methods of analysis. Biochim Biophys Acta 1764: 1890–1903.
Panagopoulos I, Fioretos T, Isaksson M, Samuelsson U, Billstrom R, Strombeck B et al. (2001). Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet 10: 395–404.
Park DT, Vuong PT, de Vos S, Douer D, Koeffler HP . (2003). Comparative analysis of genes regulated by PML/RARα and PLZF/RARα in response to retinoic acid using oligonucleotide arrays. Blood 102: 3727–3736.
Pastural E, Takahashi N, Dong WF, Bainbridge M, Hull A, Pearson D et al. (2007). RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines. Oncogene 26: 1586–1594.
Patra SK, Patra A, Zhao H, Dahiya R . (2002). DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog 33: 163–171.
Peters AH, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C et al. (2001). Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107: 323–337.
Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF et al. (2004). Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10: 1329–1335.
Qian C, Zhou MM . (2006). SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cell Mol Life Sci 63: 2755–2763.
Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406: 593–599.
Reed-Inderbitzin E, Moreno-Miralles I, Vanden-Eynden SK, Xie J, Lutterbach B, Durst-Goodwin KL et al. (2006). RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene 25: 5777–5786.
Richie ER, Schumacher A, Angel JM, Holloway M, Rinchik EM, Magnuson T . (2002). The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas. Oncogene 21: 299–306.
Rosati R, La Starza R, Veronese A, Aventin A, Schwienbacher C, Vallespi T et al. (2002). NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood 99: 3857–3860.
Rosenbauer F, Owens BM, Yu L, Tumang JR, Steidl U, Kutok JL et al. (2006). Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet 38: 27–37.
Rozman M, Camos M, Colomer D, Villamor N, Esteve J, Costa D et al. (2004). Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer 40: 140–145.
Sanchez C, Sanchez I, Demmers JA, Rodriguez P, Strouboulis J, Vidal M . (2007). Proteomics analysis of Ring1B/Rnf2 interactors identifies a novel complex with the Fbxl10/Jhdm1B histone demethylase and the Bcl6 interacting corepressor. Mol Cell Proteomics 6: 820–834.
Sanders SL, Portoso M, Mata J, Bahler J, Allshire RC, Kouzarides T . (2004). Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 119: 603–614.
Santillan DA, Theisler CM, Ryan AS, Popovic R, Stuart T, Zhou MM et al. (2006). Bromodomain and histone acetyltransferase domain specificities control mixed lineage leukemia phenotype. Cancer Res 66: 10032–10039.
Saunthararajah Y, DeSimone J . (2004). Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease. Semin Hematol 41: 11–16.
Schaefer CB, Ooi SK, Bestor TH, Bourc'his D . (2007). Epigenetic decisions in mammalian germ cells. Science 316: 398–399.
Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N et al. (2006). A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 3: e486.
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA et al. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSDI. Cell 119: 941–953.
Shilatifard A . (2006). Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu Rev Biochem 75: 243–269.
Singh M, Lavelle D, Vaitkus K, Mahmud N, Hankewych M, DeSimone J . (2007). The gamma-globin gene promoter progressively demethylates as the hematopoietic stem progenitor cells differentiate along the erythroid lineage in baboon fetal liver and adult bone marrow. Exp Hematol 35: 48–55.
Sirulnik A, Melnick A, Zelent A, Licht JD . (2003). Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol 16: 387–408.
Smallwood A, Esteve PO, Pradhan S, Carey M . (2007). Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev 21: 1169–1178.
Spannhoff A, Heinke R, Bauer I, Trojer P, Metzger E, Gust R et al. (2007). Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem 50: 2319–2325.
Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW et al. (2006). Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 16: 890–900.
Stec I, Nagl SB, van Ommen GJ, den Dunnen JT . (2000). The PWWP domain: a potential protein–protein interaction domain in nuclear proteins influencing differentiation? FEBS Lett 473: 1–5.
Stec I, Wright TJ, van Ommen GJ, de Boer PA, van Haeringen A, Moorman AF et al. (1998). WHSC1, a 90 kb SET domain-containing gene, expressed in early development and homologous to a Drosophila dysmorphy gene maps in the Wolf–Hirschhorn syndrome critical region and is fused to IgH in t(4;14) multiple myeloma. Hum Mol Genet 7: 1071–1082.
Steele JC, Torr EE, Noakes KL, Kalk E, Moss PA, Reynolds GM et al. (2006). The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 95: 1202–1211.
Steele-Perkins G, Fang W, Yang XH, Van Gele M, Carling T, Gu J et al. (2001). Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 15: 2250–2262.
Stopka T, Amanatullah DF, Papetti M, Skoultchi AI . (2005). PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 24: 3712–3723.
Su IH, Basavaraj A, Krutchinsky AN, Hobert O, Ullrich A, Chait BT et al. (2003). Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol 4: 124–131.
Suzuki M, Yamada T, Kihara-Negishi F, Sakurai T, Oikawa T . (2003). Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene 22: 8688–8698.
Tan CP, Nakielny S . (2006). Control of the DNA methylation system component MBD2 by protein arginine methylation. Mol Cell Biol 26: 7224–7235.
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. (2007). Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063.
Terranova R, Agherbi H, Boned A, Meresse S, Djabali M . (2006). Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci USA 103: 6629–6634.
Trievel RC, Beach BM, Dirk LM, Houtz RL, Hurley JH . (2002). Structure and catalytic mechanism of a SET domain protein methyltransferase. Cell 111: 91–103.
Vakoc CR, Sachdeva MM, Wang H, Blobel GA . (2006). Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol 26: 9185–9195.
van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA et al. (2005). Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 23: 3886–3896.
van Haelst MM, Hoogeboom JJ, Baujat G, Bruggenwirth HT, Van de Laar I, Coleman K et al. (2005). Familial gigantism caused by an NSD1 mutation. Am J Med Genet A 139: 40–44.
Verdel A, Jia S, Gerber S, Sugiyama T, Gygi S, Grewal SI et al. (2004). RNAi-mediated targeting of heterochromatin by the RITS complex. Science 303: 672–676.
Verdone L, Agricola E, Caserta M, Di Mauro E . (2006). Histone acetylation in gene regulation. Brief Funct Genomic Proteomic 5: 209–221.
Villa R, Morey L, Raker VA, Buschbeck M, Gutierrez A, De Santis F et al. (2006). The methyl-CpG binding protein MBD1 is required for PML-RARalpha function. Proc Natl Acad Sci USA 103: 1400–1405.
Vitoux D, Nasr R, de The H . (2007). Acute promyelocytic leukemia: new issues on pathogenesis and treatment response. Int J Biochem Cell Biol 39: 1063–1070.
Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, Martienssen RA . (2002). Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297: 1833–1837.
Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L et al. (2004). Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306: 279–283.
Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW . (2007). 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26: 77–90.
Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ . (2003). MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA 100: 8342–8347.
Yang M, Culhane JC, Szewczuk LM, Jalili P, Ball HL, Machius M et al. (2007). Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine(,). Biochemistry 46: 8058–8065.
Yang M, Gocke CB, Luo X, Borek D, Tomchick DR, Machius M et al. (2006). Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Mol Cell 23: 377–387.
Yoon YS, Jeong S, Rong Q, Park KY, Chung JH, Pfeifer K . (2007). Analysis of the H19ICR insulator. Mol Cell Biol 27: 3499–3510.
Zayed A, Couban S, Hayne O, Sparavalo N, Shawwa A, Sadek I et al. (2007). Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance. Leuk Lymphoma 48: 489–496.
Zhang X, Yang Z, Khan SI, Horton JR, Tamaru H, Selker EU et al. (2003). Structural basis for the product specificity of histone lysine methyltransferases. Mol Cell 12: 177–185.
Zhang Y, Ng HH, Erdjument-Bromage H, Tempst P, Bird A, Reinberg D . (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev 13: 1924–1935.
Zhou J, Pérès L, Honoré N, Nasr R, Zhu J, de Thé H . (2006). Dimerization-induced corepressor binding and relaxed DNA-binding specificity are critical for PML/RARA-induced immortalization. Proc Natl Acad Sci USA 103: 9238–9243.
Zhu J, Emerson SG . (2002). Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 21: 3295–3313.
Zhu J, Heyworth CM, Glasow A, Huang QH, Petrie K, Lanotte M et al. (2001). Lineage restriction of the RARalpha gene expression in myeloid differentiation. Blood 98: 2563–2567.
Acknowledgements
This study was supported by NIH Grant CA59936 and a Burroughs Welcome Foundation Clinical Scientist Award in Translational Research (JDL), the Leukemia Research Foundation (KLR) and a postdoctoral fellowship from the Basque Government (IH).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rice, K., Hormaeche, I. & Licht, J. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 26, 6697–6714 (2007). https://doi.org/10.1038/sj.onc.1210755
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210755
Keywords
This article is cited by
-
Novel evidence that the ABO blood group shapes erythropoiesis and results in higher hematocrit for blood group B carriers
Leukemia (2023)
-
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
Signal Transduction and Targeted Therapy (2023)
-
The effect of sodium valproate on differentiation of human adipose-derived stem cells into cardiomyocyte-like cells in two-dimensional culture and fibrin scaffold conditions
Cell and Tissue Research (2019)
-
SALL4 as a transcriptional and epigenetic regulator in normal and leukemic hematopoiesis
Biomarker Research (2018)
-
Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation
Cell Research (2018)
